



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.	: 10/625,626	Art unit	: 1625
Applicant	: Steven P. Adams et al.	Examiner	: Janet L. Coppins
Filing date	: July 24, 2003		
Title	: CELL ADHESION INHIBITORS		

Mail Stop AF
Customer Service Window
Randolph Building
401 Dulaney Street
Alexandria, VA 22314

DO NOT
ENTER
JLC

REPLY TO OFFICE ACTION MAILED JANUARY 13, 2005

In response to the Office Action mailed January 13, 2005 ("Office Action"), Applicants submit the following remarks.

REMARKS

Applicants thank the Examiner for indicating that claims 1-7, 10 and 11 are allowable. Claims 12-15 stand rejected.

Rejection under 35 U.S.C. § 112, first paragraph

Claims 12-15 have been rejected by the Examiner under 35 U.S.C. § 112, first paragraph, for lack of enablement. Claim 12 is independent, and claims 13-15 depend from it.

The Examiner contends that claims 12-15 are not supported by a specific asserted utility or a well established utility that would enable one skilled in the art to know how to use the claimed invention. See the Office Action at page 2. Specifically, the Examiner contends that because "claim 12 is not directed to a method of treating a disease," the Applicants have failed to set forth a definable utility. See the Office Action at page 2.

Independent claim 12 is directed to a method of preventing, inhibiting or suppressing cell adhesion in a mammal in need thereof. To satisfy enablement under 35 U.S.C. § 112, "All that is necessary is that one skilled in the art be able to practice the *claimed* invention, given the level of knowledge and skill in the art." (emphasis added) MPEP 2164.08; *see e.g. In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970). At the time of filing, one of ordinary skill in the art would have been apprised of the disclosed article, Lobb, R.R. and Hemler, M.E., "The Pathophysiologic Role of $\alpha 4$ Integrins In Vivo," *J. Clin. Invest.*, 94, pp. 1722-29 (1994) ("Lobb"), which indicates that "rapidly accumulating in vivo data... suggest that $\alpha 4$ integrin-